CM
IRWD icon

Crestline Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Crestline Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-140,000
Closed -$1.2M – 72
2019
Q3 		$1.2M Buy
+140,000
New +$1.36M 0.19% 62
2018
Q3 		– Sell
-36,536
Closed -$585K – 191
2018
Q2 		$585K Buy
+36,536
New +$541K 0.06% 218

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's IRWD Position: Q4 2019 in Review

Crestline Management sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2019, closing a stake of 140,000 shares — an estimated $1.2M sold.

Crestline Management first reported a position in IRWD in Q2 2018 and held it in 2 quarters. The position peaked at $1.2M in Q3 2019. 195 funds tracked by Wall St. Rank hold IRWD as of Q4 2019.

  • Crestline Management reported no remaining Ironwood Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Crestline Management sold 140,000 Ironwood Pharmaceuticals shares in Q4 2019, an estimated $1.2M.
  • Crestline Management first reported a position in Ironwood Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Crestline Management's Ironwood Pharmaceuticals position peaked at $1.2M in Q3 2019.
  • 195 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2019.

Based on Crestline Management's 13F filing for Q4 2019, filed 12 Feb 2020.